Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes
Journal of Diabetes Investigation · 2025
DOI: 10.1111/jdi.14391 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Investigation, 2025. Verfasst von Junko Oya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Incretins. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims/Introduction This study aimed to evaluate and compare the effectiveness of oral semaglutide after adding to or switching from incretin‐related drugs by assessing the changes in HbA1c and body weight (BW) in participants with type 2 diabetes in clinical settings. Materials and Methods A total of 368 participants were divided into groups according to antidiabetic medications before oral semaglutide treatment; incretin‐related drug‐naïve (naïve), switching from dipeptidyl peptide‐4 inhibitors (DPP‐4i) or glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) groups. Adjusted mean changes in HbA1c and BW at 6 months after oral semaglutide administration were compared among the three groups. Similar analyses were performed in the GLP‐1 RAs group between GLP‐1RAs before switching.
Results
Mean change of HbA1c in DPP‐4i and GLP‐1 RA groups was −0.67% (95% confidence interval [CI]: −0.79 to −0.54) and −0.13% (95% CI: −0.40 to 0.15), respectively, which were significantly smaller than incretin‐related drug‐naïve group; −0.85% (95% CI: −1.08 to −0.62). Mean change in BW between the naïve and DPP‐4i groups had no differences; however, these changes were lower in the GLP‐1 RA group than in the naïve group. Mean change in HbA1c between pretreatment with GLP‐1 RAs had no differences; however, the mean change in BW in the dulaglutide group was significantly higher than that in the injectable semaglutide group.
Conclusion
Oral semaglutide reduced HbA1c levels and BW after adding or switching from other incretin‐related drugs in Japanese participants with type 2 diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
ORCID-Profile: Junko Oya, Mika Shimizu, Tomoko Nagkagami
Zitieren
APA
Oya, J., Shimizu, M., Kubota, R., Suda, R., & Nagkagami, T. (2025). Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14391
Vancouver
Oya J, Shimizu M, Kubota R, Suda R, Nagkagami T. Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes. Journal of Diabetes Investigation. 2025. doi:10.1111/jdi.14391
BibTeX
@article{Oya2025,
author = {Oya, Junko and Shimizu, Mika and Kubota, Ryo and Suda, Rika and Nagkagami, Tomoko},
title = {Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes},
journal = {Journal of Diabetes Investigation},
year = {2025},
doi = {10.1111/jdi.14391}
}
EUVIMED